Research at Wells Medicine

Learn about ketamine research conducted at Wells Medicine


Wells Medicine is working with Baylor College of Medicine, Texas A&M University College of Medicine, and the University of Pittsburgh to conduct research studies on ketamine infusion therapy. These studies are important for developing our understanding of mental health conditions and ketamine therapy for mood disorders.

Wells Medicine provides a connection point between our research partners and interested patients. If you are interested in participating please contact us at any time. 

Important note: These studies provide benefits for participants, including some compensation for your time, but they do not fully cover the cost of treatments. Payment for treatment is due to Wells Medicine at the time of treatment and patients will be compensated by the research team for their participation at a later date.

BCM placeholder
TAM MaroonBox
Shield UnivPittsburgh 3color
BCM placeholder
TAM MaroonBox
Shield UnivPittsburgh 3color


Wells Medicine is working with Baylor College of Medicine, Texas A&M University College of Medicine, and the University of Pittsburgh to conduct research studies on ketamine infusion therapy. These studies are important for developing our understanding of mental health conditions and ketamine therapy for mood disorders.

Wells Medicine provides a connection point between our research partners and interested patients. If you are interested in participating please contact us at any time. 

Important note: These studies provide benefits for participants, including some compensation for your time, but they do not fully cover the cost of treatments. Payment for treatment is due to Wells Medicine at the time of treatment and patients will be compensated by the research team for their participation at a later date.

Interpersonal Psychotherapy For IV Ketamine Patients In Maintenance

remote, 29 week study


Eligibility

  • Ages 18-75
  • Receiving IV ketamine with Wells Medicine for depressive symptoms, currently receiving no more than 1 treatment per week
  • History of at least 1 acute course of ketamine treatment in the past year
  • Current diagnosis of MDD
  • Presence of suicidal ideation in last month
  • Presence of suicidal ideation with intent in last year


Reasons for Consideration

  • Compensation up to $200
  • Participation (excluding ketamine infusion appointments) is remote and can be done from everywhere
  • Free evidence-based treatment from trained clinical psychologists
  • Contribution to a pilot study exploring the feasibility and effects of concurrent psychotherapy during IV ketamine maintenance


Exclusions

  • Active or past psychotic symptoms
  • Severe alcohol use disorder (AUD)
  • Current drug use disorder (DUD)
  • Past or current manic episode; diagnosis of bipolar disorder
  • A personality disorder that may interfere with ability to engage in research trial
  • Prior IPT treatment failure
  • Engagement in concurrent psychotherapy or therapy that has been discontinued in the past 3 months
  • Pregnancy or unwillingness to use contraceptive methods
  • Safety risk warranting inpatient hospitalization per treating ketamine clinician and PI judgment

IV Ketamine with Digital Therapy Exercises

remote, year-long study


Eligibility

  • Ages 18-80
  • Receiving IV ketamine with Wells Medicine for depressive symptoms
  • Patient is pursuing an initial series of ketamine infusions. Those new to ketamine or returning after a break are eligible
  • Completion of digital onboarding prior to first infusion


Reasons for Consideration

  • Compensation up to $650-$750
  • Participation (excluding ketamine infusion appointments) is remote and can be done from anywhere
  • Enhanced clinical monitoring of your symptoms through the study assessments
  • Chance of getting free access to a portable digital treatment that may extend the duration of your depression relief and help you get the most of your ketamine treatments
  • Contribution to knowledge of how to help people like yourself


Exclusions

  • Psychosis
  • Severe substance abuse

IV Ketamine with EEG Monitoring

in-person study, includes meetings with research team


Eligibility – MDD (Major Depressive Disorder)

  • Ages 21-55
  • Receiving IV ketamine with Wells Medicine for a current or past diagnosis of depression
  • Patient is receiving maintenance infusions or pursuing a series of ketamine infusions. Those new to ketamine or returning after a break are eligible
  • Completion of in-person onboarding prior to first infusion


Eligibility – TRD (Treatment-Resistant Depression)

  • Ages 21-55
  • Patient has tried at least one antidepressant in the past
  • Receiving IV ketamine with Wells Medicine for a current or past diagnosis of depression
  • Patient is pursuing a series of ketamine infusions. Those new to ketamine or returning after a break are eligible
  • Completion of in-person onboarding prior to first infusion


Reasons for Consideration

  • Compensation up to $250 (MDD patients) or $450 (TRD patients)
  • Uber ride to first infusion (MDD patients) or first and fourth infusions (TRD patients)
  • Evaluation and consultation with a psychiatrist
  • Bloodwork
  • Contribution to knowledge of how ketamine helps people like yourself


Exclusions

  • Psychosis
  • Bipolar disorder
  • Schizophrenia
  • Pregnancy

Next Steps


Contact us if you’d like to learn more about our work with research partners. Reach us by phone call, email, text, or contact form submission: